Ark Biosciences
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
25 Lane 388 Shengrong Road Pudong New Ar...Phone Number
+86 2158350139Website
www.arkbiosciences.comRevenue
$14.2 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ark Biosciences
爱科百发 is a biopharmaceutical company focused on innovative drug development for respiratory and pediatric diseases. Their product pipeline includes groundbreaking treatments such as AK0529 for RSV, AK0901 for ADHD, and AK3280 for idiopathic pulmonary fibrosis. The company aims to address global patient needs while fostering a healthy work environment for employees and contributing to society. They are actively engaged in clinical trials and have received recognition for their innovative therapies from international health organizations.Explore more
Popular SearchesArk Biosciences IncArk Biopharmaceutical Ltd上海爱科百发生物医药技术股份有限公司SIC Code 28,283NAICS Code 32,325Show moreArk Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ark Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ark Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Ark Biosciences
Product Launch: Get notified when Ark Biosciences launches new products
Click to see if Ark Biosciences had a recent Job posting/layoffs
Ark Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ark Biosciences recently announced quarterly report
Check out if Ark Biosciences is spiking on competitors!
Check if Ark Biosciences has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Ark Biosciences as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ark Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ark Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ark Biosciences.
Ark Biosciences Tech Stack
A closer look at the technologies used by Ark Biosciences
Ark Biosciences News & Media
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substantial step forward for ArkBio in the research and development of drugs for pediatric psychiatric disorders, potentially offering new treatment options and improved therapeutic outcomes for children with ADArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. This milestone marks a significant advancement in ArkBio' RSV portfolio, offering a new potential option for preventing RSV infection for vulnerable infants susceptible to RSV. RSV is a globally prArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of ziresovir, an oral drug for treatment of respiratory syncytial virus (RSV) infection in infants and young children, have been published as an original article entitled "Ziresovir in Hospitalized Infants with RArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment
BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Active IPF Drug AK3280"at the 8th Annual IPF Summit held in Boston on August 22, 2024. AK3280 is a next-generation broad-spectrum anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF) a
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ark Biosciences
Sign Up For FreeTo access detailed company insights
爱科百发 is a biopharmaceutical company focused on innovative drug development for respiratory and pediatric diseases. Their product pipeline includes groundbreaking treatments such as AK0529 for RSV, AK0901 for ADHD, and AK3280 for idiopathic pulmonary fibrosis. The company aims to address global patient needs while fostering a healthy work environmen... Read More
